GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide ghrelin receptor agonist that produces the strongest appetite stimulation of any GHRP. It was one of the earliest GHRPs discovered and produces robust GH release but with pronounced hunger, cortisol elevation, and prolactin elevation compared to Ipamorelin. GHRP-6 is primarily used when appetite stimulation is a desired therapeutic goal (wasting conditions, difficulty eating) or when maximum GH output is needed regardless of side effects.
Quick Start
Route
SubQ injection
Start low
100 mcg SubQ
Frequency
1-3 times daily
Timing
Fasted. Extreme hunger follows.
Fasted 2+ hours. Bedtime or pre-meal (causes strong hunger). Can split into 2-3 daily doses. Strongest ghrelin receptor agonist.
❋
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
Tiered Protocols · lowest first
Conservative start
100 mcg · SubQ injection · 1-3 times daily
conservative starter
100 mcg
1-3 times daily
Standard
Appetite & Recovery
100-150 mcg · SubQ · 3x Daily
anecdotal · community
Potent ghrelin-receptor agonist - intense hunger ~15-30 min post-dose. Favored for bulking; usually paired with a GHRH.
100-150 mcg
3x Daily
Research
GH-Provocation Test (single dose)
300 mcg/kg · Oral · Single administration
human study · Mericq et al. 1995 (Eur J Endocrinol 133(4):425, PMID 7581965)
300 mcg/kg
Single administration
Reconstitution CalculatorU-100
050100u
Draw to
— units
◆
◆
◆
01
How it works
GHRP-6 activates GHS-R1a with strong ghrelin-mimetic activity, producing both GH release and potent appetite stimulation through hypothalamic hunger signaling. More cortisol and prolactin elevation than GHRP-2 or Ipamorelin. The hunger effect is often dramatic and occurs within 15-20 minutes of injection.
02
What to expect
Early
Days 1–7
Immediate: Extreme hunger. Days 1-7: Sleep improvements, body composition changes beginning.
Mid
Weeks 2–4
Weeks 2-6: Continued GH effects.
Later
Weeks 4–12
Weeks 6+: Full body composition effects with GHRH analog.
03
Evidence
HumanPresent
AnimalStrong
In-vitroPresent
Each reference below was re-fetched from its PubMed record, and the quoted sentence was
confirmed to appear in that abstract and to support the claim it sits under. Follow any of
them to read the source.
GHRP-6 has potent GH-releasing activity after IV, SubQ, intranasal, and oral administration in humans.
Growth hormone-releasing peptide 6 (GHRP-6) is a synthetic hexapeptide with a potent GH-releasing activity after intravenous, subcutaneous, intranasal and oral administration in man.
Evidence scope. Human child short-stature paper; tested dose was oral, not quick-start SubQ.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the
same as saying they are false — it marks where the evidence is missing.
Dose/frequency: 100 mcg SubQ 1-3x/day. No checked abstract stated a SubQ dose.
Extreme hunger and cortisol/prolactin at this dose. No exact-molecule abstract established these at the displayed regimen.
04
The honest take
◆
Strongest appetite GHRP
Confirmed. Most potent ghrelin-mediated hunger of any GHRP. Therapeutic advantage in cachexia/wasting.
05
Interactions & stacking
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
Documented together
BPC-157Non-overlapping
VIPNo conflict
CJC-1295 no DACGHRP + GHRH synergy.
SermorelinGHRP + GHRH synergy.
Keep separate
TesamorelinUse Ipamorelin with Tesa in standard protocols.
CJC-1295 with DACDAC maleimide.
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.
06
Side effects & safety
Commonly reported
Extreme hunger (defining feature)
Water retention
Cortisol elevation
Prolactin elevation
Lethargy
Less common & notes
Anxiety, sleep disruption.
Prolactin gynecomastia risk at high doses.
Cortisol effects more pronounced than other GHRPs.